The health insurance industry faced its worst two-day stretch in years as shares of major managed care companies continued their collapse Monday. UnitedHealth Group, the nation's largest health insurer, fell another 8% in early trading after plunging 10% in Friday's extended session. The combined market capitalization loss across major health insurers now exceeds $60 billion.

The Double Blow

Two separate but related developments converged to trigger the selloff:

Medicare Advantage Rate Proposal

On Friday evening, the Centers for Medicare & Medicaid Services proposed raising payments to Medicare Advantage insurers by a net average of just 0.09% for 2027. The proposed increase—worth approximately $700 million to the industry—fell dramatically short of analyst expectations, which had projected increases in the 4% to 6% range.

For context, insurers received a 5.06% increase for the current year. The nearly flat proposal represents the most hostile rate environment for Medicare Advantage plans since the program's inception.

DOJ Investigation

Adding to the sector's woes, UnitedHealth is currently under investigation by the Department of Justice for its Medicare billing practices. The probe, which became public in recent weeks, focuses on whether the company systematically overbilled the government by exaggerating the severity of patients' conditions.

CMS indicated it also plans to crack down on inaccurate overbilling by insurers more broadly, suggesting the regulatory pressure extends beyond UnitedHealth alone.

The Market Carnage

The scale of the selloff reflects how central Medicare Advantage has become to these companies' profits:

  • UnitedHealth Group (UNH): Down approximately 18% over two days
  • Humana (HUM): Down approximately 15% over two days
  • CVS Health (CVS): Down approximately 12% over two days
  • Elevance Health (ELV): Down approximately 6% over two days
  • Molina Healthcare (MOH): Down approximately 3% over two days

UnitedHealth alone has shed over $50 billion in market value—more than the entire market capitalization of many S&P 500 companies.

Why Medicare Advantage Matters

Medicare Advantage, which allows seniors to receive Medicare benefits through private insurers rather than traditional government-run Medicare, has been the primary growth driver for health insurance companies over the past two decades. Approximately 33 million Americans—more than half of all Medicare beneficiaries—now receive coverage through Medicare Advantage plans.

The government payment rate determines how much insurers can charge for monthly premiums and plan benefits, directly affecting their profits. A near-flat rate increase in an inflationary environment effectively means cost increases must come from somewhere—either reduced benefits, higher consumer costs, or lower insurer margins.

"The proposed rate increase, worth approximately $700 million to the industry, falls dramatically short of analyst expectations that had projected increases in the 4% to 6% range."

— Industry analyst assessment

The Billing Practices Controversy

The DOJ investigation into UnitedHealth highlights a longstanding controversy in Medicare Advantage: the incentive to "upcode" patient diagnoses. Because Medicare pays higher rates for sicker patients, insurers have motivation to document conditions that increase risk scores—even when those conditions may be questionable.

Previous government audits have found widespread issues. A 2022 analysis estimated that Medicare Advantage plans received $12 billion to $25 billion in improper payments due to inflated risk scores. The industry has contested these findings, arguing that more thorough documentation simply reflects better care coordination.

However, with both CMS and DOJ now focused on billing practices, the regulatory environment appears to be shifting decisively against insurers. The simultaneous rate pressure and billing scrutiny represent a fundamental challenge to the Medicare Advantage business model as it has operated.

UnitedHealth's Precarious Position

UnitedHealth faces particular scrutiny given its dominant position in the market. The company serves approximately 7.5 million Medicare Advantage members through its UnitedHealthcare division and owns Optum, a sprawling healthcare services company that includes physician practices, pharmacy benefits management, and data analytics.

Critics have argued that UnitedHealth's vertical integration creates potential conflicts of interest—the same company that insures patients also provides their care and manages their prescriptions. Regulatory attention on any aspect of this integrated model raises questions about the others.

UnitedHealth reports fourth-quarter earnings Tuesday morning, creating an immediate test of management's ability to reassure investors. Analysts will focus closely on guidance for 2026 and any comments about the company's response to regulatory pressures.

Broader Industry Implications

The managed care selloff carries implications beyond the directly affected companies:

Hospital Stocks

Some analysts suggest hospital operators could benefit from Medicare Advantage challenges, as traditional Medicare typically reimburses at higher rates. Hospital stocks showed modest gains Monday as investors rotated within the healthcare sector.

Pharmaceutical Companies

Drug manufacturers may face reduced pressure from pharmacy benefit managers—many owned by the same companies now under stress—though the relationship is complex and depends on how insurers respond to margin pressure.

Healthcare Policy

The Trump administration's proposed flat rates suggest a policy shift that could persist regardless of regulatory outcomes. If the administration views Medicare Advantage as having become too profitable for insurers at taxpayer expense, sustained rate pressure could become the new normal.

What Happens Next

The CMS rate proposal is preliminary, with a final rule expected in April. Industry lobbying will intensify over the coming weeks as insurers argue that inadequate rates will force them to reduce benefits or exit markets—potentially leaving seniors with fewer coverage options.

The DOJ investigation timeline is less predictable. Such probes can take years to resolve and may result in settlements, civil penalties, or in extreme cases, criminal charges. The uncertainty alone weighs on valuations.

Investment Perspective

For investors, the managed care selloff raises the question of whether this represents a buying opportunity or a permanent re-rating of the sector. Several considerations apply:

  • Valuation: After the decline, major insurers trade at lower multiples than historical averages, potentially creating value if concerns prove overblown
  • Structural risks: If the business model itself faces regulatory challenge, lower valuations may be justified regardless of short-term trading moves
  • Diversification: Companies with significant non-Medicare Advantage businesses may weather the storm better than pure plays

The $60 billion evaporated from health insurer market values in 48 hours represents one of the most dramatic sector corrections in recent memory. Whether it marks the beginning of a prolonged restructuring or an overreaction to manageable regulatory challenges will determine the industry's trajectory for years to come.